1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Espad Pharmed: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.) - Glabellar Lines, Glabellar Frown Lines | Phase 3 | Completed | Espad Pharmed | 146 | 2024-05-28 | 2025-05-07 |
Iran (1)